Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
Fish and Richardson
Accenture
Moodys
QuintilesIMS
UBS
Covington

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HABITROL

« Back to Dashboard

Clinical Trials for Habitrol

Trial ID Title Status Sponsor Phase Summary
NCT00851357 Telephone Counseling and the Distribution of Nicotine Patches to Smokers Completed California Department of Health Services Phase 3 The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1. Test if sending active nicotine patches directly will lead to a higher quit rate, compared to a condition where the quitline assists the smokers to obtain patches by other means (e.g. via their health plans). 2. Test if sending placebo patches directly will also lead to a higher quit rate. 3. Test if quitline counseling increases the quit rate when the smokers already receive the nicotine patches.
NCT00851357 Telephone Counseling and the Distribution of Nicotine Patches to Smokers Completed University of California, San Diego Phase 3 The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1. Test if sending active nicotine patches directly will lead to a higher quit rate, compared to a condition where the quitline assists the smokers to obtain patches by other means (e.g. via their health plans). 2. Test if sending placebo patches directly will also lead to a higher quit rate. 3. Test if quitline counseling increases the quit rate when the smokers already receive the nicotine patches.
NCT00954096 Nicotine Patch, Blood Flow and Oxidative Stress Study Completed National Institutes of Health (NIH) N/A This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.
NCT00954096 Nicotine Patch, Blood Flow and Oxidative Stress Study Completed University of Pennsylvania N/A This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.
NCT01145001 Enhancing a High School Based Smoking Cessation Program Completed National Institutes of Health (NIH) N/A The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (CM) + cognitive behavioral therapy intervention. Subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either CM or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that subjects receiving both active nicotine patch and CM will have higher rates of abstinence from tobacco than subjects in the other groups.
NCT01145001 Enhancing a High School Based Smoking Cessation Program Completed Yale University N/A The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (CM) + cognitive behavioral therapy intervention. Subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either CM or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that subjects receiving both active nicotine patch and CM will have higher rates of abstinence from tobacco than subjects in the other groups.
NCT01287377 Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging Completed University of California, San Diego Phase 3 The primary purpose of this study is to test the feasibility of sending pre-cessation nicotine patches and to examine the effects associated with the pre-cessation treatment phase. Specifically, this study aims to: 1. See if subjects will use pre-cessation nicotine patches. 2. See if subjects in the pre-cessation nicotine patches go on to get more nicotine patches. 3. See if pre-cessation treatment with nicotine patches leads to a decrease in number of cigarettes smoked per day. 4. See if sending 2-weeks' worth of patches is helpful to the quitting process.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Habitrol

Condition Name

Condition Name for Habitrol
Intervention Trials
Smoking Cessation 4
Nicotine Dependence 1
Healthy 1
Psychiatric Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Habitrol
Intervention Trials
Tobacco Use Disorder 1
Mental Disorders 1
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Habitrol

Trials by Country

Trials by Country for Habitrol
Location Trials
United States 5
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Habitrol
Location Trials
California 3
Connecticut 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Habitrol

Clinical Trial Phase

Clinical Trial Phase for Habitrol
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Habitrol
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Habitrol

Sponsor Name

Sponsor Name for Habitrol
Sponsor Trials
University of California, San Diego 3
California Department of Health Services 2
National Institutes of Health (NIH) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Habitrol
Sponsor Trials
Other 11
NIH 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Deloitte
QuintilesIMS
Argus Health
Daiichi Sankyo
US Army
Express Scripts
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.